Figure legends
Figure 1. (A) Study flowchart. Dynamic changes in alanine
aminotransferase (ALT) (B) and aspartate transaminase (AST) (C) levels
during follow-up. * p < 0.05; ** p <
0.01; ***p < 0.001. PeALT, persistently elevated ALT;
PnALT, persistently nomal ALT.
Figure 2. Significant differences in circulating metabolites between the
PeALT and PnALT groups. (A) Total number and main categories of
identified metabolites. (B) OPLS-DA model and (C) Volcano plots of the
PnALT vs. PeALT groups. (D) KEGG analysis results of enriched
signaling pathways. (E) The top 10 differential metabolites were ranked
by VIP values. (F) Relative intensity of the top 10 differential
metabolites between the PeALT and PnALT groups. **p <
0.01; ***p < 0.001. OPLS-DA, orthogonal projections to
latent structures discriminant analysis; KEGG, Kyoto Encyclopedia of
Genes and Genomes; VIP, variable importance in projection.
Figure 3. Differential plasma metabolites associated with PeALT risk.
(A) Correlations of the levels of differential metabolites with ALT
levels, and (B) clinical parameters. (C) ROC curve for differential
metabolites. *p < 0.05; **p < 0.01.
ROC, receiver operating characteristic.
Figure 4. NALM improves carbon tetrachloride-induced liver injury. (A)
Schematic diagram of the mouse experiment. (B, C) Comparison of serum
ALT levels in each group at 24, 48, and 72 h. (D, E) Comparison of serum
AST levels in each group at 72 h. (F, G) Representative images of
hematoxylin and eosin staining and quantification of necrotic areas in
the liver. Scale bar = 100 µm. *p < 0.05; **p< 0.01; ***p < 0.001. ”ns” indicates not
significant. NALM, N -acetyl-l-methionine; 11-DHC,
11-dehydrocorticosterone; 3-Mx, 3-methylxanthine; 7-Mx,
7-methylxanthine; 3-MA, 3-methylhippuric acid.